만성 B형간염 진료지침 업데이트

키워드

참고문헌 (42)

1. 임선영, "The epidemiology of hepatitis B virus infection in Korea", The Korean Journal of Internal Medicine, 34(5), pp.945~953 (2019), 대한내과학회[DOI]
2. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
3. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
4. Hsu YN, "Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans", Dig Dis Sci, 59, pp.865~871 (2014)
5. Yao K, "Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone", J Viral Hepat, 28, pp.1025~1033 (2021)
6. Xiao G, "Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection : a systemic review and meta-analysis", Hepatology, 61, pp.292~302 (2015)
7. Takako Inoue, "Novel biomarkers for the management of chronic hepatitis B", Clinical and Molecular Hepatology, 26(3), pp.261~279 (2020), 대한간학회[DOI]
8. Loomba R, "Advances in non-invasive assessment of hepatic fibrosis", Gut, 69, pp.1343~1352 (2020)
9. Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group", Hepatology, 24, pp.289~293 (1996)
10. Chon YE, "Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B : a meta-analysis", PLoS One, 7, pp.e44930~ (2012)
11. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
12. Andreani T, "Chronic hepatitis B virus carriers in the immunotolerant phase of infection : histologic findings and outcome", Clin Gastroenterol Hepatol, 5, pp.636~641 (2007)
13. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
14. Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
15. Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : a systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
16. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
17. Paik N, "Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia", Liver Int, 38, pp.68~75 (2018)
18. Sinn DH, "The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria", J Viral Hepat, 26, pp.1465~1472 (2019)
19. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
20. Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
21. Cornberg M, "Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference", J Hepatol, 72, pp.539~557 (2020)
22. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
23. Choi J, "Comparison of long-term clinical outcomes between spontaneous and therapy-induced HBsAg seroclearance", Hepatology, 73, pp.2155~2166 (2021)
24. Park Y, "Risk and risk score performance of hepatocellular carcinoma development in patients with hepatitis B surface antigen seroclearance", Clin Transl Gastroenterol, 12, pp.e00290~ (2021)
25. Coffin CS, "New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection", Gastroenterology, 156, pp.355~368.e3 (2019)[DOI]
26. Liu J, "The role of hepatitis B surface antigen in Nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B : a systematic review", Hepatology, 70, pp.1045~1055 (2019)
27. Jeng WJ, "Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 68, pp.425~434 (2018)
28. Mak LY, "Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection", Aliment Pharmacol Ther, 47, pp.43~54 (2018)
29. Drafting Committee for Hepatitis Management Guidelines, "Japan Society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update", Hepatol Res, 50, pp.892~923 (2020)
30. Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
31. Liu S, "Serum hepatitis B virus RNA : a new potential biomarker for chronic hepatitis B virus infection", Hepatology, 69, pp.1816~1827 (2019)
32. Kaewdech A, "Hepatitis B surface antigen, core-related antigen and HBV RNA : predicting clinical relapse after NA therapy discontinuation", Liver Int, 40, pp.2961~2971 (2020)
33. Carey I, "Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on Nucleos(T)ide analogue therapy", Hepatology, 72, pp.42~57 (2020)
34. Wu CY, "Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection", JAMA, 308, pp.1906~1914 (2012)
35. Choi J, "Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection", Hepatology, 73, pp.661~673 (2021)
36. Tsai MC, "Tenofovir is superior to entecavir on tertiary prevention for BCLC Stage 0", A hepatocellular carcinoma after curative resection, 2021, pp.11, 22~37
37. Chang JI, "Clinical outcomes of hepatitis B virus-related hepatocellular carcinoma patients with undetectable serum HBV DNA levels", Dig Dis Sci, 67, pp.4565~4573 (2022)
38. Jun BG, "Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment : a multicenter study", PLoS One, 13, pp.e0201316~ (2018)
39. Jang JW, "Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma", PLoS One, 10, pp.e0122041~ (2015)
40. Agarwal K, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection", J Hepatol, 68, pp.672~681 (2018)
41. Lampertico P, "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study", Lancet Gastroenterol Hepatol, 5, pp.441~453 (2020)
42. Byun KS, "Tenofovir alafenamide for drug-resistant hepatitis B : A randomized trial for switching from tenofovir disoproxil fumarate", Clin Gastroenterol Hepatol, 20, pp.427~437.e5 (2022)

관련 논문AI추천